{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T02:49:30Z","timestamp":1786243770870,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["EMR\/2014\/000904"],"award-info":[{"award-number":["EMR\/2014\/000904"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bbrc.2020.11.059","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T01:21:34Z","timestamp":1606267294000},"page":"461-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and HSP90 inhibitor resistances"],"prefix":"10.1016","volume":"534","author":[{"given":"Rajender Goud","family":"Arolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Malladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utsa","family":"Bhaduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher Bolisetti","family":"Gayatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi","family":"Pattamshetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-041X","authenticated-orcid":false,"given":"Vasavi","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumohan Rao","family":"Katika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aramati Bindu","family":"Madhava Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manchanahalli R.","family":"Satyanarayana Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashavantha Reddy","family":"Vudem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama Krishna","family":"Kancha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.11.059_bib1","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3324\/haematol.13207","article-title":"Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation","volume":"93","author":"Kancha","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2020.11.059_bib2","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2020.11.059_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molmed.2018.12.009","article-title":"Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology","volume":"25","author":"Sabnis","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbrc.2020.11.059_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4161\/cc.4.3.1560","article-title":"A\u00a0cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment","volume":"4","author":"von Bubnoff","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbrc.2020.11.059_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026760","article-title":"Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib","volume":"6","author":"Kancha","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.11.059_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-4608(99)00169-7","article-title":"Cytogenetics of the chronic myeloid leukemia-derived cell line K562: karyotype clarification by multicolor fluorescence in situ hybridization, comparative genomic hybridization, and locus-specific fluorescence in situ hybridization","volume":"118","author":"Gribble","year":"2000","journal-title":"Canc. Genet. Cytogenet."},{"key":"10.1016\/j.bbrc.2020.11.059_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0145-2126(00)00125-9","article-title":"Complete karyotype characterization of the K562 cell line by combined application of G-banding, multiplex-fluorescence in situ hybridization, fluorescence in situ hybridization, and comparative genomic hybridization","volume":"25","author":"Naumann","year":"2001","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bbrc.2020.11.059_bib8","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1101\/gr.772403","article-title":"PANTHER: a library of protein families and subfamilies indexed by function","volume":"13","author":"Thomas","year":"2003","journal-title":"Genome Res."},{"key":"10.1016\/j.bbrc.2020.11.059_bib9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/bioinformatics\/bth078","article-title":"Open source clustering software","volume":"20","author":"de Hoon","year":"2004","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bbrc.2020.11.059_bib10","doi-asserted-by":"crossref","first-page":"W214","DOI":"10.1093\/nar\/gkq537","article-title":"The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function","volume":"38","author":"Warde-Farley","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2020.11.059_bib11","first-page":"1","article-title":"Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia","author":"Kumar","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2020.11.059_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00532","article-title":"The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia","volume":"9","author":"Grassi","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2020.11.059_bib13","first-page":"275","article-title":"HSP90: enabler of cancer adaptation","volume":"3","author":"Jaeger","year":"2019","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.bbrc.2020.11.059_bib14","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","article-title":"BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90","volume":"100","author":"Gorre","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2020.11.059_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1365-2141.2003.04330.x","article-title":"Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL","volume":"121","author":"Topaly","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2020.11.059_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.leu.2404533","article-title":"Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines","volume":"21","author":"Barnes","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2020.11.059_bib17","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2020.11.059_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089080","article-title":"Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia","volume":"9","author":"Okabe","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.11.059_bib19","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1158\/0008-5472.CAN-08-2978","article-title":"Sorafenib induces apoptosis specifically in cells expressing BCR\/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway","volume":"69","author":"Kurosu","year":"2009","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.11.059_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12964-016-0129-y","article-title":"Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells","volume":"14","author":"Halbach","year":"2016","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bbrc.2020.11.059_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065762","article-title":"Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations","volume":"8","author":"Hsueh","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.11.059_bib22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41416-019-0688-y","article-title":"TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-na\u00efve and imatinib-resistant gastrointestinal stromal tumours","volume":"122","author":"Saito","year":"2020","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.bbrc.2020.11.059_bib23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/2159-8290.CD-12-0440","article-title":"Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer","volume":"3","author":"Sang","year":"2013","journal-title":"Canc. Discov."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20321033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20321033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:39:00Z","timestamp":1762094340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20321033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":23,"alternative-id":["S0006291X20321033"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.11.059","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and HSP90 inhibitor resistances","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.11.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}